Published in Cancer Res on August 01, 2000
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A (2007) 3.63
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol (2005) 2.24
TWIST is expressed in human gliomas and promotes invasion. Neoplasia (2005) 1.70
Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A (2001) 1.58
Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res (2003) 1.41
Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol (2004) 1.41
Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res (2008) 1.37
MET as a target for treatment of chest tumors. Lung Cancer (2008) 1.29
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol (2011) 1.23
Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol (2002) 1.18
The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell Biol (2001) 1.13
Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. Cancer Res (2010) 0.96
TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis (2005) 0.96
Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther (2009) 0.95
αB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells. Am J Pathol (2010) 0.94
An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem (2010) 0.94
Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity. Cancer Res (2009) 0.94
Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res (2005) 0.92
HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics. Int J Mol Sci (2013) 0.92
Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol (2002) 0.91
c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis (2003) 0.87
Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells. Cancer Sci (2014) 0.87
Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells. J Exp Clin Cancer Res (2009) 0.87
PTEN reconstitution alters glioma responses to c-Met pathway inhibition. Anticancer Drugs (2011) 0.86
Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer (2003) 0.85
Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One (2014) 0.85
Role of HGF/MET axis in resistance of lung cancer to contemporary management. Transl Lung Cancer Res (2012) 0.84
Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle (2014) 0.84
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas. Sci Rep (2016) 0.83
c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol (2014) 0.83
EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells. Transl Oncol (2012) 0.83
Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Br J Cancer (2016) 0.83
Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system: Review Article. Gene Ther Mol Biol (2005) 0.82
Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem (2008) 0.82
Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro. World J Surg Oncol (2012) 0.79
MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway. Oncotarget (2016) 0.78
Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5. BMC Cancer (2008) 0.77
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol (2016) 0.77
Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. Neuro Oncol (2010) 0.77
Radioresistance of Brain Tumors. Cancers (Basel) (2016) 0.76
Future directions in the evaluation of c-MET-driven malignancies. Ther Adv Med Oncol (2011) 0.76
Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer. Onco Targets Ther (2013) 0.75
MET: roles in epithelial-mesenchymal transition and cancer stemness. Ann Transl Med (2017) 0.75
Rest in Drosophila is a sleep-like state. Neuron (2000) 5.72
Hours, volume, and type of work of preregistration house officers. BMJ (1990) 5.68
Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol (1994) 5.66
Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J (1978) 4.99
Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. Am J Trop Med Hyg (1993) 4.75
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
Pattern formation and eyespot determination in butterfly wings. Science (1994) 3.98
Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A (1997) 3.19
Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A (1993) 2.86
Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest (1985) 2.64
BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science (1999) 2.54
Delayed reinforcement as an indiscriminable contingency in verbal/nonverbal correspondence training. J Appl Behav Anal (1984) 2.43
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst (1996) 2.39
Cell surface heparan sulfate mediates some adhesive responses to glycosaminoglycan-binding matrices, including fibronectin. J Cell Biol (1983) 2.35
Origin and evolution of high throughput screening. Br J Pharmacol (2007) 2.28
Pancreatic acinar cells: acetylcholine-induced membrane depolarization, calcium efflux and amylase release. J Physiol (1973) 2.12
Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol (1999) 2.07
Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med (1994) 2.03
Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science (1986) 2.00
Possible role of microtubules in thyroid secretion. Proc Natl Acad Sci U S A (1970) 2.00
A non-circadian role for cAMP signaling and CREB activity in Drosophila rest homeostasis. Nat Neurosci (2001) 1.95
Liver disease in Crohn's disease. A study of 100 consecutive patients. Scand J Gastroenterol (1971) 1.89
Sources of attention-sensitive visual event-related potentials. Brain Topogr (1994) 1.89
Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene (1994) 1.88
U73122 inhibits Ca2+ oscillations in response to cholecystokinin and carbachol but not to JMV-180 in rat pancreatic acinar cells. J Biol Chem (1992) 1.83
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene (2001) 1.82
Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini. Am J Physiol (1978) 1.80
Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology (1984) 1.79
The current use of vagotomy in the treatment of peptic ulceration. Br J Surg (1969) 1.79
Evaluation of two commercial systems for identification of coagulase-negative staphylococci to species level. Diagn Microbiol Infect Dis (1994) 1.71
Post-gastrectomy bile vomiting. Lancet (1965) 1.68
Glucocorticoids increase amylase mRNA levels, secretory organelles, and secretion in pancreatic acinar AR42J cells. J Cell Biol (1985) 1.68
HSP27 expression regulates CCK-induced changes of the actin cytoskeleton in CHO-CCK-A cells. Am J Physiol (1999) 1.67
Management of internal haemorrhoids by rubber-band ligation. Br J Surg (1971) 1.65
Response-reinforcer relationships and improved learning in autistic children. J Appl Behav Anal (1981) 1.63
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Direct versus indirect response-reinforcer relationships in teaching autistic children. J Abnorm Child Psychol (1980) 1.62
Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol (2000) 1.59
Identification of a Chlamydia trachomatis serovar E urogenital isolate which lacks the cryptic plasmid. Infect Immun (1998) 1.56
Control of pancreatic amylase release in vitro: effects of ions, cyclic AMP, and colchicine. Br J Pharmacol (1972) 1.56
Outpatient operations. I. The surgeon's view. Br Med J (1969) 1.55
Rapid evolution and selection inferred from the transcriptomes of sympatric crater lake cichlid fishes. Mol Ecol (2010) 1.55
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther (2008) 1.53
Cytochalasin B inhibits thyroid secretion. Biochem Biophys Res Commun (1971) 1.53
The effects of diversion of intestinal contents on the progress of Crohn's disease of the large bowel. Gut (1971) 1.53
Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer (1999) 1.52
Expression of interleukin-1beta in human breast carcinoma. Cancer (1997) 1.52
Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer (1997) 1.50
Resistance plasmids in Pseudomonas cepacia 4G9. J Bacteriol (1979) 1.50
Polydioxanone (PDS), a novel monofilament synthetic absorbable suture. Surg Gynecol Obstet (1981) 1.47
Determination of carbonyl groups in oxidized proteins. Methods Mol Biol (2000) 1.47
Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines. Cancer Res (2000) 1.46
Origin of transmembrane potentials in non-excitable cells. J Theor Biol (1970) 1.45
Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst (1999) 1.44
Intracellular free calcium concentrations in isolated pancreatic acini; effects of secretagogues. Biochem Biophys Res Commun (1983) 1.43
The insulin-pancreatic acinar axis. Diabetes (1985) 1.42
Cellular senescence in a cloned strain of bovine fetal aortic endothelial cells. Science (1980) 1.41
Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini. J Biol Chem (1980) 1.41
Good outcome from surgery for ampullary tumour. Aust N Z J Surg (1999) 1.41
NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J Med Chem (1997) 1.41
Colchicine-binding protein and the secretion of thyroid hormone. J Cell Biol (1972) 1.40
Regulation of pancreatic acinar cell function by intracellular calcium. Am J Physiol (1980) 1.40
The fate of ileorectal anastomosis in Crohn's disease. Gut (1971) 1.39
The incidence of recurrence in Crohn's disease. Surg Gynecol Obstet (1972) 1.38
A biologic comparison of polyglactin 910 and polyglycolic acid synthetic absorbable sutures. Surg Gynecol Obstet (1975) 1.38
Anti-AIDS agents. 15. Synthesis and anti-HIV activity of dihydroseselins and related analogs. J Med Chem (1994) 1.37
Crystal structure of ErmC', an rRNA methyltransferase which mediates antibiotic resistance in bacteria. Biochemistry (1998) 1.37
Intracellular divalent cation release in pancreatic acinar cells during stimulus-secretion coupling. I. Use of chlorotetracycline as fluorescent probe. J Cell Biol (1978) 1.37
Effect of selective and proximal gastric vagotomy on serum gastrin. Gastroenterology (1974) 1.36
Hip fracture outcomes: quality of life and functional status in older adults living in the community. Aust N Z J Med (2000) 1.36
Close and focal contact adhesions of fibroblasts to a fibronectin-containing matrix. Fed Proc (1985) 1.36
Glycosaminoglycans that bind cold-insoluble globulin in cell-substratum adhesion sites of murine fibroblasts. Proc Natl Acad Sci U S A (1980) 1.36
Crohn's disease involving the colon: an audit of clinical management. Gastroenterology (1977) 1.36
Three-dimensional structure of Fab R19.9, a monoclonal murine antibody specific for the p-azobenzenearsonate group. Proc Natl Acad Sci U S A (1989) 1.35
Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A (1996) 1.34
Neurovirulent simian immunodeficiency virus replicates productively in endothelial cells of the central nervous system in vivo and in vitro. J Virol (1994) 1.33
Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene (2011) 1.33
Partial gastrectomy: the value of permanent vitamin-B-12 therapy. Lancet (1966) 1.32
Effects of ouabain and diphenylhydantoin on transmembrane potentials, intracellular electrolytes, and cell pH of rat muscle and liver in vivo. J Physiol (1971) 1.32
Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest (1986) 1.31
The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene (2000) 1.31
Pancreatic acinar cells in monolayer culture: direct trophic effects of caerulein in vitro. Am J Physiol (1986) 1.29
Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother (1995) 1.28
Development of a diurnal resting box to collect Culiseta melanura (COQ.). Am J Trop Med Hyg (1968) 1.28
Luminescence imaging microscopy and lifetime mapping using kinetically stable lanthanide(III) complexes. J Photochem Photobiol B (2000) 1.27
BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer (2006) 1.27
Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer (1998) 1.26
Behavioral contrast and generalization across settings in the treatment of autistic children. J Exp Child Psychol (1980) 1.26
The place of surgery in Crohn's disease. Gut (1971) 1.25
Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A transactivation of the E4 promoter. J Virol (1996) 1.24
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene (2007) 1.24
Differences in hyaluronate binding to plasma and cell surface fibronectins. Requirement for aggregation. J Biol Chem (1982) 1.23
Use of gastric function tests by British gastroenterologists. Br Med J (1971) 1.22
Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat. Am J Physiol (1986) 1.21
Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med (1995) 1.21
Effects of mother-infant separation on maternal attachment behavior. Child Dev (1972) 1.20
Pancreatic acinar cells: effects of lanthanum ions on amylase release and calcium ion fluxes. J Physiol (1974) 1.19